Anti-ATM (phospho S1981) antibody [EP1890Y] (ab81292)
- Product nameAnti-ATM (phospho S1981) antibody [EP1890Y]See all ATM primary antibodies ...
- DescriptionRabbit monoclonal [EP1890Y] to ATM (phospho S1981)
- Tested applicationsWB, IHC-P, ICC/IF, IP more details
- Species reactivityReacts with: Human
Does not react withMouse, Rat
A synthetic peptide corresponding to residues surrounding serine 1981 of human ATM was used as an immunogen.
- Positive control
- HEK293 cell lysate and Human gastric carcinoma.
- General notesProduced under U.S. Patent No. 5,675,063.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%
- PurityTissue culture supernatant
- Clonality Monoclonal
- Clone numberEP1890Y
- Research Areas
Our Abpromise guarantee covers the use of ab81292 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: 1/5000 - 1/10000. Detects a band of approximately 370 kDa (predicted molecular weight: 351 kDa).|
|IHC-P||IHC-P: 1/100 - 1/250.|
|ICC/IF||ICC/IF: 1/100 - 1/250.|
- FunctionSerine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism. Also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B lymphocytes. After the introduction of DNA breaks by the RAG complex on one immunoglobulin allele, acts by mediating a repositioning of the second allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. Also involved in signal transduction and cell cycle control. May function as a tumor suppressor. Necessary for activation of ABL1 and SAPK. Phosphorylates p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin (NBN), TERF1, RAD9 and DCLRE1C. May play a role in vesicle and/or protein transport. Could play a role in T-cell development, gonad and neurological function. Plays a role in replication-dependent histone mRNA degradation. Binds DNA ends.
- Tissue specificityFound in pancreas, kidney, skeletal muscle, liver, lung, placenta, brain, heart, spleen, thymus, testis, ovary, small intestine, colon and leukocytes.
- Involvement in diseaseDefects in ATM are the cause of ataxia telangiectasia (AT) [MIM:208900]; also known as Louis-Bar syndrome, which includes four complementation groups: A, C, D and E. This rare recessive disorder is characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and sexual immaturity. AT patients have a strong predisposition to cancer; about 30% of patients develop tumors, particularly lymphomas and leukemias. Cells from affected individuals are highly sensitive to damage by ionizing radiation and resistant to inhibition of DNA synthesis following irradiation.
Note=Defects in ATM contribute to T-cell acute lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia (TPLL). TPLL is characterized by a high white blood cell count, with a predominance of prolymphocytes, marked splenomegaly, lymphadenopathy, skin lesions and serous effusion. The clinical course is highly aggressive, with poor response to chemotherapy and short survival time. TPLL occurs both in adults as a sporadic disease and in younger AT patients.
Note=Defects in ATM contribute to B-cell non-Hodgkin lymphomas (BNHL), including mantle cell lymphoma (MCL).
Note=Defects in ATM contribute to B-cell chronic lymphocytic leukemia (BCLL). BCLL is the commonest form of leukemia in the elderly. It is characterized by the accumulation of mature CD5+ B lymphocytes, lymphadenopathy, immunodeficiency and bone marrow failure.
- Sequence similaritiesBelongs to the PI3/PI4-kinase family. ATM subfamily.
Contains 1 FAT domain.
Contains 1 FATC domain.
Contains 1 PI3K/PI4K domain.
- DomainThe FATC domain is required for interaction with KAT5.
modificationsPhosphorylated by NUAK1/ARK5. Autophosphorylation on Ser-367, Ser-1893, Ser-1981 correlates with DNA damage-mediated activation of the kinase.
Acetylation, on DNA damage, is required for activation of the kinase activity, dimer-monomer transition, and subsequent autophosphorylation on Ser-1981. Acetylated in vitro by KAT5/TIP60.
- Cellular localizationNucleus. Cytoplasmic vesicle. Primarily nuclear. Found also in endocytic vesicles in association with beta-adaptin.
- A-T mutated antibody
- A-T mutated homolog antibody
- AT complementation group A antibody
- AT complementation group C antibody
- AT complementation group D antibody
- AT complementation group E antibody
- AT mutated antibody
- AT protein antibody
- AT1 antibody
- ATA antibody
- Ataxia telangiectasia gene mutated in human beings antibody
- Ataxia telangiectasia mutated antibody
- Ataxia telangiectasia mutated gene antibody
- Ataxia telangiectasia mutated homolog (human) antibody
- Ataxia telangiectasia mutated homolog antibody
- ATC antibody
- ATD antibody
- ATDC antibody
- ATE antibody
- ATM antibody
- ATM_HUMAN antibody
- DKFZp781A0353 antibody
- Human phosphatidylinositol 3 kinase homolog antibody
- MGC74674 antibody
- OTTHUMP00000232981 antibody
- Serine protein kinase ATM antibody
- Serine-protein kinase ATM antibody
- Serine/threonine-protein kinase ATM antibody
- T cell prolymphocytic leukemia antibody
- Tefu antibody
- TEL1 antibody
- TEL1, telomere maintenance 1, homolog antibody
- TELO1 antibody
- Telomere fusion protein antibody
- TPLL antibody
Anti-ATM (phospho S1981) antibody [EP1890Y] images
ab81292 staining ATM (phospho S1981) in Human primary fibroblasts treated with IR (5Gy) by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with paraformaldehyde, permeabilized with 0.2% Triton X-100 and blocked with 2% BSA for 2 hours at room temperature. Samples were incubated with primary antibody (1/500 in PBS + 2% BSA) for 14 hours at 4°C. An Alexa Fluor® 488-conjugated Goat anti-rabbit IgG polyclonal (1/1000) was used as the secondary antibody.
Left - ATM (phospho S1981), Right - DAPI + merge.
ab81292 staining ATM in Human HeLa cell by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with paraformaldehyde, permeabilized with 0.1% Triton X-100 and blocked with 1% serum for 1 hour at 22°C. Samples were incubated with primary antibody (1/250 in TBS-Tween20 + 5% BSA) for 1 hour at 22°C. A TRITC-conjugated Donkey anti-rabbit IgG polyclonal (1/150) was used as the secondary antibody. Cells treated with 10 Gy IR and allowed to recover for 30 minutes before fixed.
ab81292, 1/100, staining Human gastric carcinoma by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
All lanes : Anti-ATM (phospho S1981) antibody [EP1890Y] (ab81292) at 1/10000 dilution
Lane 1 : HEK293 cell lysates untreated.
Lane 2 : HEK293 cell lysates treated with doxorubicin.
Lysates/proteins at 10 µg per lane.
Lane 1 : HRP labelled goat anti-rabbit at 1/2000 dilution
Lane 2 : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size : 351 kDa
Observed band size : 370 kDa (why is the actual band size different from the predicted?)
ICC/IF image of ab81292 stained HepG2 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab81292,1µg/ml) overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti-rabbit IgG - H&L, pre-adsorbed (ab96899) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
ab81292 showing positive staining in Breast carcinoma tissue.
ab81292 showing positive staining in Normal tonsil tissue.
ab81292 showing positive staining in Cervical carcinoma tissue.
ab81292 showing positive staining in Endometrial carcinoma tissue.
References for Anti-ATM (phospho S1981) antibody [EP1890Y] (ab81292)
This product has been referenced in:
- Fenton AL et al. The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair. Nucleic Acids Res 41:4080-92 (2013). WB ; Human . Read more (PubMed: 23449221) »
- Wu SY et al. Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity. Nucleic Acids Res 41:4650-9 (2013). WB ; Human . Read more (PubMed: 23449220) »